Marksans Pharma Limited — Updates, 11-02-2025: Press Release (Revised)

Marksans Pharma Ltd. reported significant financial achievements, with Q3 revenue rising 16.3% YoY to Rs. 681.8 crore, marking 12 consecutive quarters of double-digit growth. The company's PAT reached an all-time high of Rs. 105.1 crore, driven by robust sales in the US market, which grew 37.1% YoY. Gross profit also saw notable expansion, climbing 22.4% YoY to Rs. 383.5 crore, alongside a gross margin increase of 279 bps to 56.2%.

The nine-month results reflect an 18.4% YoY revenue increase to Rs. 1,914.4 crore, supported by new product launches and market share gains. Despite facing some EBITDA margin pressure due to recent investments and rising freight costs, the company anticipates ongoing growth supported by upcoming product launches and increased output from its TEVA facility.

Looking ahead, Marksans is focusing on leveraging new product initiatives, maintaining a positive outlook as it continues to expand in key markets, particularly the US and Europe.